A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA
Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or
niacin. The patient's cardiovascular risks are assessed to determine if National Cholesterol
Education Program's Adult Treatment Panel III (NCEP ATP III) guidelines for low density
lipoprotein (LDL) reduction were achieved between the three groups. Secondary measures
examine the safety issues with liver function test (LFT) monitoring and rhabdomyolysis.
High-density lipoproteins (HDL) elevations are monitored between the three groups to
determine efficacy as a secondary outcome.
Phase:
Phase 4
Details
Lead Sponsor:
Tuscaloosa Research & Education Advancement Corporation
Collaborator:
American Society of Health-System Pharmacists Research and Education Foundation